Dr. Agarwal's Eye Hospital Limited
Dr. Agarwal's Eye Hospital Limited Fundamental Analysis
Dr. Agarwal's Eye Hospital Limited (DRAGARWQ.BO) shows moderate financial fundamentals with a PE ratio of 32.48, profit margin of 15.50%, and ROE of 30.44%. The company generates $4.4B in annual revenue with strong year-over-year growth of 24.38%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 67.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze DRAGARWQ.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakDRAGARWQ.BO struggles to generate sufficient returns from assets.
Valuation Score
WeakDRAGARWQ.BO trades at a premium to fair value.
Growth Score
ExcellentDRAGARWQ.BO delivers strong and consistent growth momentum.
Financial Health Score
ModerateDRAGARWQ.BO shows balanced financial health with some risks.
Profitability Score
ModerateDRAGARWQ.BO maintains healthy but balanced margins.
Key Financial Metrics
Is DRAGARWQ.BO Expensive or Cheap?
P/E Ratio
DRAGARWQ.BO trades at 32.48 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, DRAGARWQ.BO's PEG of 3.19 indicates potential overvaluation.
Price to Book
The market values Dr. Agarwal's Eye Hospital Limited at 7.21 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 13.02 times EBITDA. This signals the market has high growth expectations.
How Well Does DRAGARWQ.BO Make Money?
Net Profit Margin
For every $100 in sales, Dr. Agarwal's Eye Hospital Limited keeps $15.50 as profit after all expenses.
Operating Margin
Core operations generate 22.05 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $30.44 in profit for every $100 of shareholder equity.
ROA
Dr. Agarwal's Eye Hospital Limited generates $9.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Dr. Agarwal's Eye Hospital Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Dr. Agarwal's Eye Hospital Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
DRAGARWQ.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.19
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.21
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.90
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.06
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.33
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.30
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How DRAGARWQ.BO Stacks Against Its Sector Peers
| Metric | DRAGARWQ.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.48 | 29.45 | Worse (Expensive) |
| ROE | 30.44% | 779.00% | Weak |
| Net Margin | 15.50% | -24936.00% (disorted) | Strong |
| Debt/Equity | 1.06 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.33 | 4.65 | Neutral |
| ROA | 9.58% | -19344.00% (disorted) | Weak |
DRAGARWQ.BO outperforms its industry in 1 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Dr. Agarwal's Eye Hospital Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
126.64%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
299.41%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
136.58%
Industry Style: Defensive, Growth, Innovation
High Growth